Project Grant R44NS137868
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$500K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53202, USA
Similar Awards
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $794,967 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to develop a murine glioblastoma model for evaluating oncolytic herpes simplex virus (HSV) therapy. The key objective is to create a mouse model with brain tumors that are permissive to HSV-1 infection. This...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $420,251 to Brigham & Women's Hospital Inc. to develop an oncolytic virus therapy combined with engineered stem cells and immunomodulators for treating glioblastoma, the most lethal primary brain tumor. The key products and services to be delivered under this...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $449,203 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to investigate the interaction between glioblastoma (GBM) brain tumors and the subventricular zone (SVZ) neurogenic niche. The study aims to enhance understanding of the mechanisms driving the increased...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $431,750 R21 project grant (CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders) to Rutgers, The State University of New Jersey to study the role of the RIPK3 protein in protecting neurons from excitotoxicity during Zika virus infection. The two-year project will use a combination of pharmacogenetics, imaging, molecular biology, and electrophysiology to investigate how RIPK3...
This $460,940 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The award to the University of Texas MD Anderson Cancer Center will leverage single cell and bulk profiling approaches in induced pluripotent stem cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the impact of maternal viral infections and inflammation on immune programming within the fetal brain and lymphoid organs in a non-human primate model. The $3,305,720 award, granted on July 12, 2024, with a completion date of May 31, 2029, will be used to: 1) Determine innate immune pathways...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research Program (CFDA 93.395), provides $1,881,613 in funding to The General Hospital Corporation (Massachusetts General Hospital) to develop and evaluate new oncolytic virus-based immunotherapies for glioblastoma, a deadly brain cancer. The key objectives are to create oncolytic herpes simplex viruses (OHSVs) that can stimulate the immune system and inhibit the immunosuppressive adenosine pathway...
This federal Project Grant award, identified as K08NS136766, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $234,359 award supports research to investigate the role of the receptor tyrosine kinase MERTK in cognitive and behavioral dysfunction in mice with congenital Zika virus (ZIKV) infection. The research aims to understand how increased MERTK...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $635,173 to support research on understanding the mechanisms by which the MYCN oncogene drives an immunosuppressive tumor microenvironment in high-risk neuroblastoma. The key products or services to be delivered under this grant include: Characterizing the types and...
This $443,354 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate novel therapeutic targets for diffuse midline gliomas (DMG), an aggressive pediatric brain tumor. The research aims to leverage unbiased approaches to identify vulnerabilities in the metabolic pathways of DMG cells harboring the H3K27M mutation, which...